Presbyopia and night vision disturbance will follow myopia as a clinical focus for Vyluma. Navneet Puri, PhD, the company’s founder, chairman, and CEO, shares what is next.
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.